BIT
PVLA

BlackRock Institutional Trust’s Palvella Therapeutics PVLA Stock Holding History

BlackRock Institutional Trust’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$17K Hold
149
– – ﹤0.01% 3772
2016
Q3 		$22K Hold
149
– – ﹤0.01% 3802
2016
Q2 		$19K Buy
+149
New +$22.8K ﹤0.01% 3824

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust's PVLA Position: Q4 2016 in Review

BlackRock Institutional Trust held its Palvella Therapeutics (PVLA) position steady in Q4 2016 at 149 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3772.

BlackRock Institutional Trust first reported a position in PVLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $22K in Q3 2016. 24 funds tracked by Wall St. Rank hold PVLA as of Q4 2016.

  • BlackRock Institutional Trust held 149 shares of Palvella Therapeutics worth $17K as of Q4 2016.
  • BlackRock Institutional Trust left its Palvella Therapeutics share count unchanged in Q4 2016.
  • Palvella Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3772 holding.
  • BlackRock Institutional Trust first reported a position in Palvella Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Institutional Trust's Palvella Therapeutics position peaked at $22K in Q3 2016.
  • 24 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.